ALLOThe cash register is ringing
Allogene Therapeutics wrapped up its previously announced public offering of common stock on April 16, raising about $200.4 million in gross proceeds before underwriting discounts and expenses. The deal included 87.5 million shares sold at $2.00 each, plus another 12.7 million shares after underwriters partly exercised their option.
Why this matters
If you’re holding ALLO, this is one of those classic biotech tradeoffs: more money in the bank, but also more shares on the table. The company now has a bigger cushion to fund its pipeline, which is exactly what a cash-hungry drug developer wants when it’s still in the “prove it” phase.
At the same time, dilution is the not-so-fun side dish here. When a company raises capital by selling stock, existing shareholders get a smaller slice of the pie — even if the pie itself just got bigger.
Big picture
This isn’t a surprise ambush; it’s the finish line of a deal that had already been announced. But for investors, the important part is simple: Allogene now has more runway, and the market gets to decide whether that runway is worth the extra share count.